Four new drugs on the market: Abiraterone, belatacept, vandetanib and fidaxomycine;Actualités thérapeutiques : L'abiratérone, le bélatacept, le vandétanib et la fidaxomycine

Annales Pharmaceutiques Francaises

Volumn 71, Issue 2, 2013, Pages 95-103

  Monneret, C ^a  

^a INSTITUT CURIE   (France)

Author keywords

Abiraterone; Alpharadin; Belatacept; Cabazitaxel; Denosumab; Enzulatamide; Fidaxomicin; Sipuleucel T; Vandetanib

Indexed keywords

ABIRATERONE ACETATE; BELATACEPT; CYCLOSPORIN; FIDAXOMICIN; TACROLIMUS; VANDETANIB;

BACTEROIDES; CANCER SPECIFIC SURVIVAL; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; GRAFT REJECTION; HUMAN; KIDNEY FUNCTION; KIDNEY GRAFT; KIDNEY INJURY; KIDNEY TRANSPLANTATION; OUTCOME ASSESSMENT; PROPHYLAXIS; PROSTATE CANCER; RISK ASSESSMENT; SHORT SURVEY; T LYMPHOCYTE; THYROID CANCER;

AMINOGLYCOSIDES; ANDROSTENOLS; ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; ENZYME INHIBITORS; HUMANS; IMMUNOCONJUGATES; IMMUNOSUPPRESSIVE AGENTS; MALE; PIPERIDINES; PROSTATIC NEOPLASMS; QUINAZOLINES; THYROID NEOPLASMS;

EID: 84877922507     PISSN: 00034509     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharma.2013.01.004     Document Type: Short Survey

References (21)

1. Kawalec P., Paszulewicz A., Holko P., Pilc A. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. A systematic review and meta-analysis. Arch Med Sci 2012, 8(5):767-775.
2. Heidenreich A, Scholz HJ, Rogenhofer S, Arsov C, Retz M, et al. Cabazitaxel plus prednisone for metastatic castration-resistant prostate cancer progressing after docetaxel: results from the German Compassionate-use Programme. Eur Urol 2012, , pii: S0302-2838(12)01011-1. doi:10.1016/j.eururo.2012.08.058.
3. Paller C.J., Carducci M.A., Philips G.K. Management of bone metastases in refractory prostate cancer-role of denosumab. Clin Interv Aging 2012, 7:363-372.
4. Fizazi K., Scher H.I., Molina A., Logothetis C.J., Chi K.N., Jones R.J. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2012, 13(10):983-992.
5. Fizazi K., Albiges L., Massard C., Escudier B., Loriot Y. Novel and bone-targeted agents for CRPC. Ann Oncol 2012, 23(Suppl. 10):264-267.
6. Scher H.I., Fizazi K., Saad F., Taplin M.E., Sternberg C.N., et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012, 367(13):1187-1197.
7. Croke J, Leung E, Segal R, Malone S. Clinical benefits of alpharadin in castrate-chemotherapy-resistant prostate cancer: case report and literature review. BMJ Case Rep 2012, , pii: bcr2012006540. doi:10.1136/bcr-2012-006540.
8. Beaudreuil S., Durrbach A., Kriaa F., Charpentier B. Une nouvelle molécule originale, immunosuppressive, en transplantation d'organe M/S. Med Sci (Paris) 2006, 22(4):354-355.
9. Pestana J.O., Grinyo J.M., Vanrenterghem Y., Becker T., Campistol Durrbach A. Three-year outcomes from BENEFIT-EXT: a phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys. Am J Transplant 2012, 12(3):630-639.
10. Durrbach A., Pestana J.M., Pearson T., Vincenti F., Garcia V.D., et al. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT EXT-STUDY). Am J Transplant 2010, 10(3):547-557.
11. Pestana J.O., Grinyo J.M., Vanrenterghem Y., Becker T., Campistol J.M., et al. Three-year outcomes from BENEFIT-EXT: a phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys. Am J Transplant 2012, 12(3):630-639.
12. Sassolas G., Hafdi-Nejjari Z., Remontet L., Bossard N., Belot A., et al. Thyroid cancer: is the incidence rise abating?. Eur J Endocrinol 2009, 160(1):71-79.
13. Schlumberger M., Sherman S.I. Clinical trials for progressive differentiated thyroid cancer: patient selection, study design, and recent advances. Thyroid 2009, 19:1393-1400.
14. Wells S.A., Robinson B.G., Gagel R.F., Dralle H., Gaging J.A., et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 2012, 30(2):134-141.
15. Leboulleux S., Bastholt L., Krause T., de la Fouchardiere C., Tennvall J., et al. Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. Lancet Oncol 2012, 13(9):897-905.
16. Wells S.A., Gosnell J.E., Gagel R.F., Moley J., Pfister, et al. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 2010, 28:767-772.
17. Robinson B.G., Paz-Ares L., Krebs A., Vasselli J., Haddad R. Vandetanib (100mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Endocrinol Metab 2010, 95:2664-2671.
18. Consulté le 11 décembre 2012. http://www.institut-oncologie-thoracique.com/archives/niveau_de_mutation/fusion-kif5b-ret.
19. Chao B.H., Briesewitz R., Villalona-Calero M.A. RET fusion genes in non-small-cell lung cancer. J Clin Oncol 2012, 30(35):4439-4441.
20. Louie T.J., Miller M.A., Mullane K.M., Weiss K., Lentnek A., Golan Y., et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011, 364(5):422-431.
21. Goldstein E.J., Citron D.M., Sears P., Babakhani F., Sambol S.P., Gerding D.N. Comparative susceptibilities to fidaxomicin (OPT-80) of isolates collected at baseline, recurrence, and failure from patients in two phase III trials of fidaxomicin against Clostridium difficile infection. Antimicrob Agents Chemother 2011, 55(11):5194-5199.